A COST-EFFECTIVENESS ANALYSIS OF RIVAROXABAN IN COMBINATION WITH ACETYLSALICYLIC ACID (ASA) IN ADULT PATIENTS WITH CORONARY ARTERY DISEASE (CAD) OR SYMPTOMATIC PERIPHERAL ARTERY DISEASE (PAD) AT HIGH RISK OF ISCHAEMIC EVENTS

被引：0
|
作者：
Pinheiro, B. [1 ]
Gouveia, M. [2 ]
Alarcao, J. [1 ]
Ascencao, R. [1 ]
Borges, M. [3 ]
机构：
[1] Univ Lisbon, Ctr Estudos Med Baseada Evidencia, Fac Med, Lisbon 11, Portugal
[2] Catolica Lisbon Sch Business & Econ, Lisbon 11, Portugal
[3] Univ Lisbon, Fac Med, Lab Farmacol Clin & Terapeut, Lisbon, Portugal
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 01期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
POSB50
引用
收藏
页码：S69 / S69
页数：1
相关论文
共 50 条
  • [1] COST-EFFECTIVENESS OF RIVAROXABAN 2.5MG IN COMBINATION WITH ASPIRIN IN TREATMENT OF PATIENTS WITH CORONARY ARTERY DISEASE (CAD) OR PERIPHERAL ARTERY DISEASE (PAD) IN GREECE
    Kalogeropoulou, M.
    Gkouvitsos, I
    Barlogiannis, T.
    Bowrin, K.
    Briere, J. B.
    Millier, A.
    Karabis, A.
    VALUE IN HEALTH, 2019, 22 : S555 - S555
  • [2] COST-EFFECTIVENESS OF RIVAROXABAN 2.5 MG BID WITH ASA VERSUS ASA MONOTHERAPY IN PATIENTS WITH CORONARY ARTERY DISEASE OR PERIPHERAL ARTERY DISEASE IN SLOVAKIA
    Psota, M.
    Psenkova, M.
    Briere, J. B.
    Bowrin, K.
    Millier, A.
    Paulis, L.
    Krockova, R.
    VALUE IN HEALTH, 2019, 22 : S571 - S571
  • [3] COST-EFFECTIVENESS OF RIVAROXABAN IN THE TREATMENT OF PATIENTS WITH CHRONIC CORONARY ARTERY DISEASE OR PERIPHERAL ARTERY DISEASE IN SPAIN
    Gonzalez-Juanatey, J. R.
    Gomez, J. J.
    Lozano, F. S.
    Valle, A.
    Bowrin, K.
    Briere, J. B.
    Llorac, A.
    Millier, A.
    de Miguel, C.
    Diana, N.
    VALUE IN HEALTH, 2020, 23 : S493 - S494
  • [4] Clinical implications and cost-effectiveness analysis of rivaroxaban in patients with coronary artery disease or peripheral arterial disease in the Netherlands
    Spoorendonk, J. A.
    Briere, J-B
    Bowrin, K.
    Millier, A.
    Coppens, M.
    Tempelaar, S.
    Verheggen, B.
    JOURNAL OF MEDICAL ECONOMICS, 2021, 24 (01) : 1231 - 1239
  • [5] BUDGET IMPACT OF RIVAROXABAN 2.5MG IN COMBINATION WITH ASPIRIN IN TREATMENT OF PATIENTS WITH CORONARY ARTERY DISEASE (CAD) OR PERIPHERAL ARTERY DISEASE (PAD) IN GREECE
    Kalogeropoulou, M.
    Gkouvitsos, I
    Barlogiannis, T.
    Bowrin, K.
    Briere, J. B.
    Millier, A.
    Karabis, A.
    VALUE IN HEALTH, 2019, 22 : S553 - S553
  • [6] Cost-effectiveness analysis of screening for peripheral artery disease in patients with coronary artery disease in China: A Markov model
    Xing, Yuanming
    Qiu, Yulan
    Yang, Luting
    Yuan, Zuyi
    Wang, Yan
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2023, 371 : 420 - 426
  • [7] COST-EFFECTIVENESS OF CORONARY AND PERIPHERAL ARTERY DISEASE TREATMENTS
    Soini, E.
    Virtanen, O.
    Briere, J. B.
    Bowrin, K.
    Millier, A.
    VALUE IN HEALTH, 2019, 22 : S546 - S546
  • [8] Cost-effectiveness of rivaroxaban plus aspirin versus aspirin alone in patients with stable coronary artery disease or peripheral artery disease: a systematic review
    Arabloo, Jalal
    Rezaei, Mohammad Ali
    Makhtoumi, Vahid
    Sadiani, Zahra Mollaei
    Rezapour, Aziz
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2025, 81 (02) : 279 - 290
  • [9] Rivaroxaban to reduce the risk of major cardiovascular events in patients with chronic coronary artery disease or peripheral artery disease: a narrative review
    Abdul-Rahman, Toufik
    Roy, Poulami
    Herrera-Calderon, Ranferi Eduardo
    Mueller-Gomez, Jann Ludwig
    Lisbona-Buzali, Marcos
    Ulusan, Sebahat
    Awuah, Wireko Andrew
    Kuchma, Nataliia
    Mehta, Nikhil
    Agrawal, Ankit
    Altibi, Ahmed
    Gupta, Rahul
    EXPERT OPINION ON DRUG SAFETY, 2025,
  • [10] COST-EFFECTIVENESS ANALYSIS OF MYOSTRAIN IN SUSPECTED CORONARY ARTERY DISEASE PATIENTS
    Stojanovic, I
    Schneider, J. E.
    VALUE IN HEALTH, 2018, 21 : S216 - S216
12345